VectivBio Holding AG
VectivBio Holding AG (VECT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · VECT · as of Jun 9, 2026
Key Statistics
Explore VectivBio Holding AG Data
vect stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 100.0%
The VECT analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month price target is $18.00, representing +6.70% upside from the current price of $16.87.
Competitors & Peers
vect competitorsVECT
ALBO
CBIO
CMRX
CTIC
EQRXStock Performance
Full HistoryAbout VectivBio Holding AG
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeut…
what is vectivbio holding ag · vect stock overview · vectivbio holding ag company profile · who is vectivbio holding ag ceo · vect NASDAQ · vectivbio holding ag headquarters · vectivbio holding ag business segments
About Stock Overview & Key Data
VectivBio Holding AG (VECT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 8, 2021. As of the latest trading session, VECT stock price is $16.87, with a market capitalization of $1.1B. The stock has returned +204.79% over the past 12 months and +92.58% year-to-date.
According to 3 Wall Street analysts, the consensus rating for VectivBio Holding AG stock is Buy, with an average 12-month price target of $18.00. In fiscal year 2022, VectivBio Holding AG reported revenue of $27.3M and net income of -$93.7M. For detailed data — including VectivBio Holding AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, VectivBio Holding AG (VECT) stock price is $16.87. The stock is traded on NASDAQ under the ticker symbol VECT. The 52-week range is $4.25 – $16.98.